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ABSTRACT Mary Lopez-Perez works on immunology and pathogenesis of malaria.
In this mSphere of Influence article, she reflects on how the paper “Functional anti-
bodies against VAR2CSA in nonpregnant populations from Colombia exposed to
Plasmodium falciparum and Plasmodium vivax” by S. Gnidehou, J. Doritchamou, E. M.
Arango, A. Cabrera, et al. (Infect Immun 82:25652573, 2014, https://doi.org/10.1128/
IAI.01594-14) made her cautious of relying exclusively on recombinant proteins when
evaluating antibody responses.
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Plasmodium falciparum, followed by Plasmodium vivax, is the parasite species re-sponsible for most of the malaria cases worldwide every year, with 228 million cases
estimated in 2018 (1). Children under 5 years old and pregnant women are the most
vulnerable groups affected by malaria, since they lack specific protective immunity
against the parasites. This protection is mainly antibody mediated and predominantly
targets P. falciparum erythrocyte membrane protein 1 (PfEMP1), the major antigen
expressed on the infected erythrocyte (IE) surface (2). The susceptibility of pregnant
women to malaria is related to VAR2CSA (3), a particular PfEMP1 variant that binds to
an unusually low-sulfated form of chondroitin sulfate A (CSA) found in the placental
intervillous spaces, allowing the selective accumulation of IEs in the placenta (4, 5).
Therefore, it is generally assumed that parasites expressing this variant do not thrive in
nonpregnant individuals. Indeed, the levels of VAR2CSA-specific IgG in plasma increase
with parity and inhibit IEs binding to CSA. These antibodies are restricted to pregnancy,
with only a few reports of low levels among P. falciparum-exposed men, children, and
nulligravidae. This fact and the identification of the CSA-binding domain in VAR2CSA
constitute the rationale for the development of a VAR2CSA-based vaccine to protect
against placental malaria. Such vaccines are currently being tested in phase 1a/1b
clinical trials (ClinicalTrials.gov. NCT02647489 and NCT02658253).
Since the intensity of P. falciparum transmission in Colombia is low, malaria during
pregnancy, including placental malaria, occurs infrequently (6–8). It was therefore
highly unexpected when Gnidehou et al. (9) reported high levels and frequencies (50
to 70%) of VAR2CSA-specific IgG in Colombia, not only in pregnant women with or
without malaria infection but also among nulligravidae, men, and children living in
areas of the country where malaria is endemic. To evaluate the antibody levels,
Gnidehou et al. (9) had used recombinant domains (DBL3X, DBL5, and ID1-ID2) of
VAR2CSA produced in baculovirus-infected Sf9 insect cells (referred to as BIC). Their
data showed that men and children from Colombia had higher antibody levels to the
ID1-ID2 domain than pregnant women. In contrast, their control samples from Benin
(men, children, and nulligravidae women) had antibodies below the cutoff level against
all the domains, in agreement with numerous reports from Africa. The authors pro-
posed that the high VAR2CSA reactivity among Colombians was related to cross-
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reactive antibodies induced by the P. vivax antigen PvDBP (10). Both P. falciparum and
P. vivax are transmitted in Colombia, whereas P. vivax transmission is very low in Africa
(1). Thus, the findings pointed to a novel and unanticipated mode of acquisition of
VAR2CSA-specific IgG in Colombia. Indeed, the report not only suggested that the
current understanding of immunity to placental malaria needed to be revised for areas
where several malaria parasite species are cotransmitted but called the rationale
underpinning the development of VAR2CSA-based vaccines against placental malaria
into question.
To shed additional light on the prevalence and specificity of IgG recognizing
VAR2CSA in this population (11), we decided to measure antibody response in a
different set of samples from Colombia, using a full-length recombinant VAR2CSA
(FV2BIC) expressed in the same system used by Gnidehou et al. (9). Our samples
included Colombian pregnant women, children, and men with malaria or previously
exposed to the disease and a control group of nonpregnant malaria-exposed women
from Ghana. In agreement with Gnidehou and colleagues, we found that FV2BIC-specific
IgG antibodies were frequent among pregnant and nonpregnant individuals. Surpris-
ingly, we found that the FV2BIC-specific IgG levels in the Colombian samples were
positively correlated with IgG levels to another PfEMP1 full-length recombinant protein
(FV6BIC), expressed in the same system but a variant not restricted to parasites infecting
pregnant women. It was surprising because such a correlation would not be expected
intuitively and because it was not observed in samples from Ghana or in individuals
exposed exclusively to P. vivax, arguing against the idea of species cross-reactive
antibodies as the explanation. Moreover, levels of IgG recognizing the recombinant
VAR2CSA protein did not show the expected correlation with IgG to the corresponding
native protein expressed on the surfaces of IEs. It thus appeared that the Colombian
plasma samples contained IgG recognizing epitopes in the recombinant proteins that
are absent from the native counterpart—epitopes that might not even be specific to
malaria. To test this, we expressed the FV2 protein in mammalian CHO cells (FV2CHO)
rather than in insect cells. Indeed, the levels of IgG to FV2CHO were very low in plasma
from nonpregnant Colombian individuals and did not correlate with the levels of
FV2BIC-specific IgG. Furthermore, they positively correlated with the native protein only
among pregnant women. Finally, the IgG reactivity to FV2BIC could not be depleted by
incubation with FV2CHO.
We did not pursue the identity of the epitopes in the FV2BIC proteins recognized by
samples from Colombia, as we considered that beyond the scope of our work. However,
our investigation did not yield support for the suggestion by Gnidehou et al. (10) that
PvDBP, a P. vivax antigen, induces cross-reactive antibodies that recognize VAR2CSA.
Thus, our data show that responses to recombinant proteins can be seriously mislead-
ing if not checked carefully against data obtained with the corresponding native
proteins. An independent report (12) of remarkable differences in the ability of native
and recombinant PfEMP1 proteins to bind to endothelial receptors implicated in
malaria pathogenesis emphasizes this caveat.
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